Previous 10 | Next 10 |
LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a Fireside chat and one-on-one investor...
AC Immune (NASDAQ:ACIU) has announced that CFO Joerg Hornstein will leave the company in the second half to pursue a new opportunity. Christopher Roberts, Associate Vice President, Finance, has been promoted to VP, Finance and named interim CFO. The biopharmaceutical company also announ...
Howard Donovan appointed Chief HR Officer, joins executive committee Joerg Hornstein, CFO, will leave to pursue new role Chris Roberts promoted to Vice President, Finance and appointed Interim CFO Julian Snow promoted to Vice President, U.S. Finance & Corporate Development...
a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially enables accelerated development of targeted therapeutics and additional a-syn diagnostics Another first for validated Morphomer ® discovery technology platform in developing small molecules ab...
AC Immune press release (NASDAQ:ACIU): FY Non-GAAP EPS of -CHF0.99. As of December 31, 2021 the Company had a total cash balance of CHF 198.2 million, composed of CHF 82.2 million in cash and cash equivalents and CHF 116.0 million in short-term fin...
Seven clinical data readouts expected in 2022 Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022 Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H2 2022 Initiation of ACI-24 anti-Abeta vaccine Phase 1b/2 trial...
LAUSANNE, Switzerland, March 21, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, will host a key opinion leader (KOL) webinar on alpha-synuclein (a-syn) as a target in ...
ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including Parkinson’s disease, Lewy Body Dementia, MSA and others AC Immune to host ...
Five presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD TM ) AC Immune’s Chief Medical Officer to participate in expert forum on translational drug discovery for a-synucleinopathies LAUSANNE, Swit...
AC Immune (NASDAQ:ACIU) reported interim 10-week data from a high-dose cohort of a phase 1b/2a trial evaluating ACI-35.030, a phosphorylated-Tau (pTau) vaccine candidate in people with early Alzheimer’s disease (AD). The company said new interim data showed that the high-dose of A...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...